Nice rejects another breast cancer drug

Cancer charities have greeted the move with disappointment and said drugs of this type are "particularly valuable". The drug fulvestrant (known commercially as Faslodex and manufactured by AstraZeneca) is used to delay the growth of a certain type of breast cancer and has previously been rejected for other types of breast cancer. But Nice's draft guidance said it does not believe the evidence submitted by the drug's manufacturer proves it works significantly better than existing treatments and so its widespread use would not be a good use of resources. The body said the evidence th...